Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityNo recent work listed

Yi Zhu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8783-319X; OpenAlex author ID A5049166487. Sources: OpenAlex.

Their work

Papers
19 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
53
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: none · 2014: 6 papers · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper

Papers 19

  1. Exosomes Derived from Pancreatic Cancer Cells Induce Osteoclast Differentiation Through the miR125a-5p/TNFRSF1B Pathway. First author DOI 10.2147/ott.s282319↗
  2. Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine. Co-author DOI 10.1016/j.biopha.2019.109521↗
  3. FHL3 promotes pancreatic cancer invasion and metastasis through preventing the ubiquitination degradation of EMT associated transcription factors. Co-author DOI 10.18632/aging.102564↗
  4. Corrigendum to "GFRα2 prompts cell growth and chemoresistance through down-regulating tumor suppressor gene PTEN via Mir-17-5p in pancreatic cancer" [Cancer Le… Co-author DOI 10.1016/j.canlet.2019.03.031↗
  5. MicroRNA-300 promotes apoptosis and inhibits proliferation, migration, invasion and epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway b… Co-author DOI 10.1002/jcb.26270↗
  6. PIK3R3 Promotes Metastasis of Pancreatic Cancer via ZEB1 Induced Epithelial-Mesenchymal Transition. First author DOI 10.1159/000489382↗
  7. PEG10 overexpression induced by E2F-1 promotes cell proliferation, migration, and invasion in pancreatic cancer. First author DOI 10.1186/s13046-017-0500-x↗
  8. The clinical value, regulatory mechanisms, and gene network of the cancer-testis gene STK31 in pancreatic cancer. Co-author DOI 10.18632/oncotarget.16814↗
  9. GFRα2 prompts cell growth and chemoresistance through down-regulating tumor suppressor gene PTEN via Mir-17-5p in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2016.06.016↗
  10. NPM1 activates metabolic changes by inhibiting FBP1 while promoting the tumorigenicity of pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.4167↗
  11. Snail recruits Ring1B to mediate transcriptional repression and cell migration in pancreatic cancer cells. Co-author DOI 10.1158/0008-5472.can-14-0181↗
  12. Elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates natural killer cell dysfunction. Last author DOI 10.1186/1471-2407-14-738↗
  13. Specific-detection of clinical samples, systematic functional investigations, and transcriptome analysis reveals that splice variant MUC4/Y contributes to the … Co-author DOI 10.1186/s12967-014-0309-8↗
  14. H2AK119Ub1 and H3K27Me3 in molecular staging for survival prediction of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.2126↗
  15. hsa-miR-141 downregulates TM4SF1 to inhibit pancreatic cancer cell invasion and migration. Co-author DOI 10.3892/ijo.2013.2189↗
  16. Pancreatic cancer counterattack: MUC4 mediates Fas-independent apoptosis of antigen-specific cytotoxic T lymphocyte. Co-author DOI 10.3892/or.2014.3016↗
  17. High expression of Galectin-1 in pancreatic stellate cells plays a role in the development and maintenance of an immunosuppressive microenvironment in pancreat… Co-author DOI 10.1002/ijc.26290↗
  18. Association of increased DNA methyltransferase expression with carcinogenesis and poor prognosis in pancreatic ductal adenocarcinoma. First author DOI 10.1007/s12094-012-0770-x↗
  19. The increase in the expression and hypomethylation of MUC4 gene with the progression of pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s12032-010-9683-0↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yi Miao · 10 shared papers, 2011–2020 · strength 0.54
  2. Hao Chen · 6 shared papers, 2014–2019 · strength 0.34
  3. Baiyong Shen · 6 shared papers, 2014–2019 · strength 0.34
  4. Yunpeng Peng · 4 shared papers, 2014–2020 · strength 0.30
  5. Jiangning Gu · 4 shared papers, 2015–2019 · strength 0.26
  6. Chenghong Peng · 5 shared papers, 2014–2019 · strength 0.26
  7. Qian Zhan · 4 shared papers, 2014–2019 · strength 0.26
  8. Kuirong Jiang · 5 shared papers, 2012–2017 · strength 0.24
  9. Wentao Gao · 5 shared papers, 2011–2017 · strength 0.24
  10. Yizhao Zhou · 2 shared papers, 2020–2021 · strength 0.24
  11. Yulian Wu · 2 shared papers, 2020–2021 · strength 0.24
  12. Jishu Wei · 4 shared papers, 2012–2018 · strength 0.22
  13. Jingjing Zhang · 4 shared papers, 2014–2017 · strength 0.21
  14. Xiaxing Deng · 4 shared papers, 2014–2018 · strength 0.21
  15. Xiaole Zhu · 2 shared papers, 2018–2020 · strength 0.19
  16. Zekuan Xu · 5 shared papers, 2011–2014 · strength 0.18
  17. Junli Wu · 3 shared papers, 2012–2020 · strength 0.17
  18. Lingdi Yin · 2 shared papers, 2017–2018 · strength 0.16
  19. Xinchun Liu · 2 shared papers, 2017–2018 · strength 0.16
  20. Zipeng Lu · 3 shared papers, 2012–2017 · strength 0.14
  21. Gang Wei · 2 shared papers, 2016–2019 · strength 0.14
  22. Xiaxing Deng · 2 shared papers, 2016–2019 · strength 0.14
  23. Yiqun Fan · 1 shared paper, 2021 · strength 0.13
  24. Shi Chen · 2 shared papers, 2014–2018 · strength 0.12
  25. Jingjing Zhang · 3 shared papers, 2011–2014 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.